As of March 31, 2025, Belite Bio (BLTE, Financial) reported holding $157.4 million in cash and other liquid assets, including time deposits and U.S. Treasury bills. The company has achieved a critical milestone in the development of Tinlarebant, marked by a positive interim analysis of their Phase 3 DRAGON trial earlier this year. Dr. Tom Lin, Chairman and CEO, expressed enthusiasm about the supportive feedback concerning safety and efficacy from the DSMB, as they aim to conclude the trial by the end of 2025. The company is committed to advancing its late-stage clinical programs to offer new treatments for degenerative retinal diseases, addressing a significant unmet medical need.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Belite Bio Inc (BLTE, Financial) is $85.00 with a high estimate of $110.00 and a low estimate of $50.00. The average target implies an upside of 39.60% from the current price of $60.89. More detailed estimate data can be found on the Belite Bio Inc (BLTE) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Belite Bio Inc's (BLTE, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
